Abstract
In this chapter, we provide a systematic overview of the published guidelines and validation procedures for fluorescence in situ hybridization (FISH) probes for clinical diagnostic use. FISH probes—which are classified as molecular probes or analyte-specific reagents (ASRs)—have been extensively used in vitro for both clinical diagnosis and research. Most commercially available FISH probes in the United States are strictly regulated by the U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), the Centers for Medicare & Medicaid Services (CMS) the Clinical Laboratory Improvement Amendments (CLIA), and the College of American Pathologists (CAP). Although home-brewed FISH probes—defined as probes made in-house or acquired from a source that does not supply them to other laboratories—are not regulated by these agencies, they too must undergo the same individual validation process prior to clinical use as their commercial counterparts. Validation of a FISH probe involves initial validation and ongoing verification of the test system. Initial validation includes assessment of a probe’s technical specifications, establishment of its standard operational procedure (SOP), determination of its clinical sensitivity and specificity, development of its cutoff, baseline, and normal reference ranges, gathering of analytics, confirmation of its applicability to a specific research or clinical setting, testing of samples with or without the abnormalities that the probe is meant to detect, staff training, and report building. Ongoing verification of the test system involves testing additional normal and abnormal samples using the same method employed during the initial validation of the probe.
Key words
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
FDA (1996) Federal register. http://www.federalregister.gov/agencies/food-and-drug-administration. Accessed 6 Jan 2016
American College of Medical Genetics (1993) Prenatal interphase fluorescence in situ hybridization (FISH) policy statement. Am J Hum Genet 53(2):526–527
Schad CR, Dewald GW (1995) Building a new clinical test for fluorescence in situ hybridization. Appl Cytogenet 21:1–4
Wiktor AE, Van Dyke DL, Stupca PJ et al (2006) Preclinical validation of fluorescence in situ hybridization assays for clinical practice. Genet Med 8(1):16–23. doi:10.109701.gim.0000195645.00446.61
American College of Medical Genetics (2000) Technical and clinical assessment of fluorescence in situ hybridization: an ACMG/ASHG position statement. I. Technical considerations. Genet Med 2(6):356–361
Wolff DJ, Bagg A, Cooley LD et al (2007) Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn 9(2):134–143. doi:10.2353/jmoldx.2007.060128
Saxe DF, Persons DL, Wolff DJ et al (2012) Validation of fluorescence in situ hybridization using an analyte-specific reagent for detection of abnormalities involving the mixed lineage leukemia gene. Arch Pathol Lab Med 136(1):47–52. doi:10.5858/arpa.2010-0645-SA
Mascarello JT, Hirsch B, Kearney HM et al (2011) Technical standards and guidelines: fluorescence in situ hybridization. Genet Med 13(7):667–675. doi:10.1097/GIM.0b013e3182227295
National Committee for Clinical Laboratory Standards (NCCLS) (2004) Fluorescence In Situ Hybridization Methods for Medical Genetics: Approved Guideline. NCCLS Document MM7-A. [ISBN1-56238-524-0]. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087–1898 USA
Clinical and Laboratory Standards Institute (CLSI) (2013) Fluorescence In Situ Hybridization Methods for Clinical Laboratories; Approved Guideline—Second Edition. CLSI document MM07-A2 [ISBN 1-56238-885-1] Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087-1898 USA
Zhao L, Hayes K, Glassman A (1998) A simple efficient method of sequential G-banding and fluorescence in situ hybridization. Cancer Genet Cytogenet 103(1):62–64
Stupca PJ, Meyer RG, Dewald GW (2005) Using controls for molecular cytogenetic testing in clinical practice. J Assoc Genet Technol 31(1):4–8
Hajdinjak T (2008) UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 26(6):646–651. doi:10.1016/j.urolonc.2007.06.002
Kearney HM, Thorland EC, Brown KK et al (2011) American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. Genet Med 13(7):680–685. doi:10.1097/GIM.0b013e3182217a3a
Dewald G, Stallard R, Alsaadi A et al (2000) A multicenter investigation with D-FISH BCR/ABL1 probes. Cancer Genet Cytogenet 116(2):97–104
Thall PF, Jacoby D, Zimmerman SO (1996) Estimating genomic category probabilities from fluorescent in situ hybridization counts with misclassification. J R Stat Soc C-Appl 45(4):431–446
Ciolino AL, Tang ME, Bryant R (2009) Statistical treatment of fluorescence in situ hybridization validation data to generate normal reference ranges using Excel functions. J Mol Diagn 11(4):330–333. doi:10.2353/jmoldx.2009.080101
Papoulis A (1980) Citation classic – probability, random-variables, and stochastic-processes. Cc/Eng Tech Appl Sci 19:14
Dewald GW, Wyatt WA, Juneau AL et al (1998) Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 91(9):3357–3365
Acknowledgement
We thank Laura L. Russell, Scientific Editor at the Department of Scientific Publications, the University of Texas MD Anderson Cancer Center for her excellent editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Gu, J., Smith, J.L., Dowling, P.K. (2017). Fluorescence In Situ Hybridization Probe Validation for Clinical Use. In: Wan, T. (eds) Cancer Cytogenetics. Methods in Molecular Biology, vol 1541. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6703-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6703-2_10
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6701-8
Online ISBN: 978-1-4939-6703-2
eBook Packages: Springer Protocols